HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Heart Test Laboratories, Inc.

d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company")

, an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 11:30 am ET.

To access the live webcast, please visit the Investors page of the HeartSciences website. To ask a question, please feel free to send your questions ahead of time to [e-mail]. The webcast will be available for replay on HeartSciences’ investor relations website at https://ir.heartsciences.com/.

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® Device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Contacts:

HeartSciences Gene Gephart [phone] (US) [e-mail]

Investors Gilmartin Group Vivian Cervantes [e-mail]